Germline mutations in pancreatic cancer and potential new therapeutic options.
Name:
17291-253223-1-PB.pdf
Size:
1.070Mb
Format:
PDF
Description:
Open access full text article
Affiliation
Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, United KingdomIssue Date
2017-04-20
Metadata
Show full item recordAbstract
Due to short-lived treatment responses in unresectable disease, pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers. There is availability of new information about germline and sporadic mutations in the deoxyribonucleic acid (DNA) damage repair pathway in PDAC in recent decades and the expectation is that novel targeted therapies will thus be developed. A variety of germline mutations (BRCA2, BRCA1, PALB2, CDKN2A, ATM, TP53 and mismatch repair genes MLH1, MSH2, MSH6) have been reported in these patients with the highest prevalence being BRCA1/2. Positive results have been reported with the use of targeted therapies, particularly poly (ADP-ribose) polymerase inhibitors in BRCA-mutated ovarian and breast cancers, and their use is currently being investigated in germline-mutated pancreatic cancer. The aim of this review is to provide an outline of germline DNA damage repair mutations in pancreatic cancer and their effect on the incidence, outcomes and responses to different therapeutic options.Citation
Germline mutations in pancreatic cancer and potential new therapeutic options. 2017 OncotargetJournal
OncotargetDOI
10.18632/oncotarget.17291PubMed ID
28488580Type
ArticleLanguage
enISSN
1949-2553ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.17291